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P
eople with diabetes, particularly
those with type 2 diabetes, exhibit
increased platelet reactivity. Hyper-
glycemia contributes to greater platelet
reactivity through direct effects and by
promoting glycation of platelet proteins.
Hypertriglyceridemia increases platelet
reactivity. Both insulin resistance and insu-
lindeﬁciencyincreaseplateletreactivity.In-
sulin antagonizes activation of platelets.
Thus, relative or absolute deﬁciency of in-
sulinwouldbeexpectedtoincreaseplatelet
reactivity.Diabetesisassociatedwithoxida-
tive stress and inﬂammation. Resultant en-
dothelial dysfunction promotes activation
ofplateletsbydecreasingproductionofni-
tricoxide(NO)thatattenuatesplateletre-
activity. Oxidative stress accentuates this
effect by attenuating activity of NO and
promoting platelet activation. Inﬂamma-
tion and platelet activation are recipro-
cally related. Inﬂammation promotes
platelet activation that, in turn, promotes
inﬂammation. Accordingly, improved
metaboliccontrolachievedwithregimens
that improve insulin sensitivity and pre-
serve pancreatic -cell function is likely
todecreaseplateletreactivityandenhance
effects of antiplatelet agents.
Platelets from subjects with diabetes
exhibit increased reactivity (i.e., in-
creased propensity to activate in response
to a stimulus) (1). This review highlights
factors that contribute to increased plate-
let reactivity. Type 2 diabetes is more
prevalent than type 1 diabetes and is as-
sociated with a substantially increased
risk of macrovascular complications. Ac-
cordingly, this review focuses on platelet
reactivityinsubjectswithtype2diabetes.
Key aspects of type 2 diabetes are insulin
resistance, metabolic abnormalities in-
cluding hyperglycemia, and systemic ab-
normalitiesincludingoxidativestressand
inﬂammation. The inﬂuence of each of
theseabnormalitiesonplateletfunctionis
addressed.
Metabolic abnormalities and platelet
function
Induction of hyperglycemia and hyperin-
sulinemia in healthy subjects without di-
abetes increases platelet reactivity (2).
Consistent with this observation, im-
proved glycemic control has been associ-
atedwithdecreasedplateletreactivity(3).
Hyperglycemia can increase platelet reac-
tivity by inducing nonenzymatic glyca-
tion of proteins on the surface of the
platelet. Such glycation decreases mem-
brane ﬂuidity and increases the propen-
sity of platelets to activate (4). Osmotic
effect of glucose is a second mechanism
by which hyperglycemia can increase
platelet reactivity (5). We found that brief
exposure of platelets in vitro to hypergly-
cemia or a similar concentration of man-
nitol increased their reactivity. Activation
of protein kinase C is a third mechanism
by which hyperglycemia can increase
platelet reactivity (6). Protein kinase C is an
essential mediator of platelet activation.
People with diabetes exhibit in-
creased expression of the surface glycopro-
teinsIbandIIb/IIIa(7).Theseglycoproteins
mediate platelet adhesion and adherence.
Thus, greater expression would be antic-
ipated to increase the functional activity,
ifnotthereactivity,ofplateletsinsubjects
with diabetes. Expression of these adhe-
sion proteins correlates with hyperglyce-
mia reﬂected by A1C. Hyperglycemia
appears to promote platelet activity by in-
creasing megakaryocyte production of
glycoproteins.
Although hyperglycemia is the sine
quanonofdiabetes,abnormalitiesoflipid
metabolism are uniformly observed. Peo-
ple with diabetes typically manifest hy-
pertriglyceridemia. VLDL that is rich in
triglycerides increases platelet reactivity
(8). This effect appears to be mediated, in
part, by apolipoprotein E. Thus, both hy-
perglycemia and hypertriglyceridemia in-
crease platelet reactivity in subjects with
diabetes.
Insulin resistance, insulin
deﬁciency, and platelet function
Most people who are destined to develop
type 2 diabetes exhibit insulin resistance
andconsequenthyperinsulinemiafor1–2
decadesbeforemanifestingdiabetes.Dur-
ing this interval, hyperinsulinemia com-
pensates for insulin resistance and fasting
hyperglycemiaisnotevident.Obesitycan
induce and exacerbate insulin resistance.
Apoptosis of pancreatic -cells leads to a
relative and ultimately absolute deﬁ-
ciency of insulin. Progressive insulin de-
ﬁciency is seen after type 2 diabetes
becomesmanifest.Bothinsulinresistance
and insulin deﬁciency can alter platelet
reactivity.
Insulinantagonizestheeffectofplate-
let agonists such as collagen, ADP, epi-
nephrine, and platelet-activating factor
(9). This antagonism is mediated by acti-
vation of an inhibitory G protein by insu-
lin receptor substrate (IRS)-1 (10).
Insulin resistance reﬂects impaired insu-
lin signaling, predominantly mediated by
IRS.Thus,resistancebytheplatelettothe
effects of insulin (relative insulin deﬁ-
ciency) or absolute deﬁciency of insulin
attenuates insulin-mediated antagonism
of platelet activation and thereby in-
creases platelet reactivity.
Obese subjects who are insulin resis-
tant exhibit increased activation of plate-
lets. Platelet activation identiﬁed by the
measurement of a thromboxane metabo-
lite in urine and the concentration of
CD40 ligand in blood was increased in
obese compared with lean women. De-
creased insulin resistance achieved by
weightlossortreatmentwithpioglitazone
(without weight loss) reduced the con-
centrations of these markers (11). An-
other study quantiﬁed the concentration
of platelet-derived microparticles in
blood; microparticles that are released
during the activation of platelets were in-
creased in obese subjects (12). Similar to
results in the previous study, the concen-
tration of microparticles was decreased
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Cardiology Unit, Department of Medicine, Cardiovascular Research Institute, University of Ver-
mont, Burlington, Vermont.
Corresponding author: David J. Schneider, david.schneider@uvm.edu.
Received 14 October 2008 and accepted 8 November 2008.
DOI: 10.2337/dc08-1865
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
Bench to Clinic Symposia
EDITORIAL REVIEW
DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009 525after weight reduction (12). Thus, insulin
resistance appears to increase the activa-
tionofplatelets,consistentwithincreased
platelet reactivity.
As mentioned previously, subjects
with type 2 diabetes exhibit progressive
deﬁciency of insulin as a consequence of
pancreatic -cell apoptosis. A conse-
quence of pancreatic -cell apoptosis is
absolute deﬁciency of insulin. Accord-
ingly,therelativedeﬁciencyofinsulinim-
parted by insulin resistance is magniﬁed
by the superimposition of insulin deﬁ-
ciency. Platelet reactivity that is increased
in obese subjects manifesting insulin re-
sistance will be greater when type 2 dia-
betes is manifest and accompanied by
absolute deﬁciency of insulin.
A recent study suggests that resis-
tance to the effects of insulin is apparent
in pathways independent of IRS in addi-
tiontothosedependentonIRS(13).Con-
sistent with this observation, platelets
from subjects with insulin resistance
show diminished sensitivity to the ac-
tions of NO and prostacyclin (14,15).
NO and prostacyclin are produced by
theintactendotheliumandretardplatelet
activation by increasing intraplatelet con-
centrations of cyclic nucleotides, cyclic
guanosine monophosphate, and cyclic
adenosine monophosphate. Thus, resis-
tance of the platelet to the effects of these
agents promotes increased platelet reac-
tivity. Accordingly, insulin resistance at-
tenuates tonic antagonism of platelet
activation and thereby increases platelet
reactivity.
Oxidative stress, inﬂammation, and
platelet function
Diabetes is associated with systemic in-
ﬂammation and oxidative stress that may
contribute to increased platelet reactivity.
Superoxide has been shown to increase
platelet reactivity (16). One mechanism
by which superoxide may increase plate-
let reactivity is by enhancing intraplatelet
release of calcium after activation (17). In
addition, superoxide limits the biologic
activity of NO (18). Attenuating the effect
of NO would be anticipated to increase
platelet reactivity. Oxidative stress impairs
endothelial function and reduces produc-
tionofNO(19).Impairedendothelialfunc-
tion also decreases the production of
prostacyclin (20). Accordingly, oxidative
stress that accompanies diabetes pro-
motes greater platelet reactivity through
direct effects on platelets and by inducing
endothelial dysfunction. Endothelial dys-
function increases platelet reactivity be-
cause of decreased production and
effect of NO and decreased production
of prostacyclin.
Thrombosis that entails platelet acti-
vation is intimately intertwined with in-
ﬂammation. People with diabetes exhibit
increased markers of both platelet activa-
tionandinﬂammation(21).Inparticular,
cross-talk between platelets and leuko-
cytes ampliﬁes leukocyte activation both
by platelet activation and by platelet reac-
tivity (22). For example, the release of
platelet-activating factor by leukocytes
primes platelets for activation and in-
creases the extent to which they activate
in response to other agonists (23).
An additional mechanism by which
inﬂammation can increase platelet reac-
tivity is by increasing expression of pro-
teins that participate in the activation of
platelets. For example, subjects with dia-
betes exhibit increased expression of Fc
receptortypeIIa(FcRIIa)andassociated
increased platelet activation in response
to collagen (24). Inﬂammation appears to
increaseexpressionofFcRIIa,andatten-
uation of inﬂammation decreases expres-
sion of FcRIIa (25). Thus, inﬂammation
that accompanies diabetes contributes to
increased platelet reactivity that, in turn,
contributes to greater inﬂammation.
Summary
Diabetes is associated with increased
platelet reactivity. Factors that contribute
directly to greater platelet reactivity in-
cludemetabolicabnormalitiessuchashy-
perglycemia and hyperlipidemia, both
insulin resistance (relative insulin deﬁ-
ciency)andabsoluteinsulindeﬁciency,as
well as associated conditions such as oxi-
dative stress, inﬂammation, and endothe-
lial dysfunction. Although antiplatelet
therapyisnecessarytosuppressincreased
platelet reactivity, control of hyperglyce-
mia with regimens that decrease insulin
resistance and prevent apoptosis of pan-
creatic-cellsshoulddecreaseplateletre-
activity and enhance the efﬁcacy of
antiplatelet therapy by addressing root
causes of increased reactivity.
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